论文部分内容阅读
目的研究嗜铬蛋白A在哮喘发病中的表达及孟鲁司特的调控作用。方法将SD大鼠随机分为哮喘组、对照组和孟鲁司特组,采用卵白蛋白复制哮喘模型,分别采用免疫组化法和实时荧光定量PCR法检测大鼠肺组织嗜铬蛋白A及其mRNA表达情况,测定嗜铬蛋白A表达的光密度(OD)值强度,分析嗜铬蛋白A与其mRNA表达的相关性。结果哮喘组大鼠嗜铬蛋白A的表达水平(OD值0.34±0.05)高于对照组(OD值0.21±0.06)(P<0.01),嗜铬蛋白A mRNA表达水平(RQ值4.02±0.95)高于对照组(P<0.01);孟鲁司特组嗜铬蛋白A的表达水平(OD值0.28±0.04)低于哮喘组(P<0.05),嗜铬蛋白A mRNA表达水平(RQ值3.67±0.78)与哮喘组,差异无统计学意义(P>0.05)。大鼠肺组织嗜铬蛋白A与其mRNA的表达水平呈直线正相关(r=0.635,P<0.01)。结论嗜铬蛋白A可能参与哮喘的炎症机制,孟鲁司特能下调嗜铬蛋白A的表达。
Objective To study the expression of Chromogranin A in the pathogenesis of asthma and the regulatory effect of Montelukast. Methods SD rats were randomly divided into asthma group, control group and montelukast group. The model of ovalbumin-induced asthma was used. The levels of chromogranin A and its expression in rat lung were detected by immunohistochemistry and real-time fluorescence quantitative PCR respectively. The expression of Chromogranin A (OD) was measured. The correlation between Chromogranin A and its mRNA expression was analyzed. Results The expression level of Chromogranin A mRNA in asthmatic rats was significantly higher than that in the control group (OD 0.21 ± 0.06, P <0.01) and the level of Chromogranin A mRNA (RQ 4.02 ± 0.95) (0.80 ± 0.04) in the montelukast group were lower than those in the asthma group (P <0.05), while the levels of Chromogranin A mRNA (RQ value: 3.67 ± 0.78) and asthma group, the difference was not statistically significant (P> 0.05). There was a linear positive correlation between the expression of Chromogranin A (P <0.01) and the expression of Chromogranin A (P <0.01). Conclusion Chromogranin A may be involved in the inflammatory mechanism of asthma. Montelukast can down-regulate the expression of Chromogranin-A.